128 related articles for article (PubMed ID: 18675252)
1. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide.
Shan L; Pang L; Zhang R; Murgolo NJ; Lan H; Hedrick JA
Biochem Biophys Res Commun; 2008 Oct; 375(1):69-73. PubMed ID: 18675252
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling.
Kysenius K; Muggalla P; Mätlik K; Arumäe U; Huttunen HJ
Cell Mol Life Sci; 2012 Jun; 69(11):1903-16. PubMed ID: 22481440
[TBL] [Abstract][Full Text] [Related]
3. High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.
Dong B; Singh AB; Azhar S; Seidah NG; Liu J
Atherosclerosis; 2015 Apr; 239(2):364-74. PubMed ID: 25682035
[TBL] [Abstract][Full Text] [Related]
4. In Silico Insights into Protein-protein Interaction Disruptive Mutations in the PCSK9-LDLR complex.
Martin WR; Lightstone FC; Cheng F
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32106405
[TBL] [Abstract][Full Text] [Related]
5. Repurposing an endogenous degradation domain for antibody-mediated disposal of cell-surface proteins.
Schmitt J; Poole E; Groves I; Owen DJ; Graham SC; Sinclair J; Kelly BT
EMBO Rep; 2024 Mar; 25(3):951-970. PubMed ID: 38287192
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibition protects mice from food allergy.
Lorant V; Klein M; Garçon D; Sotin T; Frey S; Cheminant MA; Ayer A; Croyal M; Flet L; Rimbert A; Colas L; Cariou B; Bouchaud G; Le May C
Transl Res; 2024 Mar; ():. PubMed ID: 38471633
[TBL] [Abstract][Full Text] [Related]
7. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor.
Zhang Y; Eigenbrot C; Zhou L; Shia S; Li W; Quan C; Tom J; Moran P; Di Lello P; Skelton NJ; Kong-Beltran M; Peterson A; Kirchhofer D
J Biol Chem; 2014 Jan; 289(2):942-55. PubMed ID: 24225950
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies.
Seidah NG
Curr Pharm Des; 2013; 19(17):3161-72. PubMed ID: 23317404
[TBL] [Abstract][Full Text] [Related]
9. PCSK9: a convertase that coordinates LDL catabolism.
Horton JD; Cohen JC; Hobbs HH
J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S172-7. PubMed ID: 19020338
[TBL] [Abstract][Full Text] [Related]
10. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
Chan JC; Piper DE; Cao Q; Liu D; King C; Wang W; Tang J; Liu Q; Higbee J; Xia Z; Di Y; Shetterly S; Arimura Z; Salomonis H; Romanow WG; Thibault ST; Zhang R; Cao P; Yang XP; Yu T; Lu M; Retter MW; Kwon G; Henne K; Pan O; Tsai MM; Fuchslocher B; Yang E; Zhou L; Lee KJ; Daris M; Sheng J; Wang Y; Shen WD; Yeh WC; Emery M; Walker NP; Shan B; Schwarz M; Jackson SM
Proc Natl Acad Sci U S A; 2009 Jun; 106(24):9820-5. PubMed ID: 19443683
[TBL] [Abstract][Full Text] [Related]
11. Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.
Kosenko T; Golder M; Leblond G; Weng W; Lagace TA
J Biol Chem; 2013 Mar; 288(12):8279-8288. PubMed ID: 23400816
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial.
Moriarty PM; Jacobson TA; Bruckert E; Thompson PD; Guyton JR; Baccara-Dinet MT; Gipe D
J Clin Lipidol; 2014; 8(6):554-561. PubMed ID: 25499937
[TBL] [Abstract][Full Text] [Related]
13. Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.
Du F; Hui Y; Zhang M; Linton MF; Fazio S; Fan D
J Biol Chem; 2011 Dec; 286(50):43054-61. PubMed ID: 22027821
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.
McNutt MC; Kwon HJ; Chen C; Chen JR; Horton JD; Lagace TA
J Biol Chem; 2009 Apr; 284(16):10561-70. PubMed ID: 19224862
[TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
[TBL] [Abstract][Full Text] [Related]
16. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo.
Ni YG; Di Marco S; Condra JH; Peterson LB; Wang W; Wang F; Pandit S; Hammond HA; Rosa R; Cummings RT; Wood DD; Liu X; Bottomley MJ; Shen X; Cubbon RM; Wang SP; Johns DG; Volpari C; Hamuro L; Chin J; Huang L; Zhao JZ; Vitelli S; Haytko P; Wisniewski D; Mitnaul LJ; Sparrow CP; Hubbard B; Carfí A; Sitlani A
J Lipid Res; 2011 Jan; 52(1):78-86. PubMed ID: 20959675
[TBL] [Abstract][Full Text] [Related]
17. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor.
Duff CJ; Scott MJ; Kirby IT; Hutchinson SE; Martin SL; Hooper NM
Biochem J; 2009 May; 419(3):577-84. PubMed ID: 19196236
[TBL] [Abstract][Full Text] [Related]
18. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A
N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.
White CM
Ann Pharmacother; 2015 Dec; 49(12):1327-35. PubMed ID: 26424774
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]